Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;46(6):1029-1042.
doi: 10.1002/jimd.12681. Epub 2023 Oct 3.

CRISPR/Cas9-based functional genomics strategy to decipher the pathogenicity of genetic variants in inherited metabolic disorders

Gerard Muñoz-Pujol  1 , Olatz Ugarteburu  1 , Eulàlia Segur-Bailach  1 , Sonia Moliner  1 , Susana Jurado  1 , Glòria Garrabou  2 , Mariona Guitart-Mampel  2 , Judit García-Villoria  1 , Rafael Artuch  3 , Carme Fons  4 , Antonia Ribes  1 , Frederic Tort  1
Affiliations

CRISPR/Cas9-based functional genomics strategy to decipher the pathogenicity of genetic variants in inherited metabolic disorders

Gerard Muñoz-Pujol et al. J Inherit Metab Dis. 2023 Nov.

Abstract

The determination of the functional impact of variants of uncertain significance (VUS) is one of the major bottlenecks in the diagnostic workflow of inherited genetic diseases. To face this problem, we set up a CRISPR/Cas9-based strategy for knock-in cellular model generation, focusing on inherited metabolic disorders (IMDs). We selected variants in seven IMD-associated genes, including seven reported disease-causing variants and four benign/likely benign variants. Overall, 11 knock-in cell models were generated via homology-directed repair in HAP1 haploid cells using CRISPR/Cas9. The functional impact of the variants was determined by analyzing the characteristic biochemical alterations of each disorder. Functional studies performed in knock-in cell models showed that our approach accurately distinguished the functional effect of pathogenic from non-pathogenic variants in a reliable manner in a wide range of IMDs. Our study provides a generic approach to assess the functional impact of genetic variants to improve IMD diagnosis and this tool could emerge as a promising alternative to invasive tests, such as muscular or skin biopsies. Although the study has been performed only in IMDs, this strategy is generic and could be applied to other genetic disorders.

Keywords: CRISPR/Cas9; HAP1; cell models; inherited metabolic disorders; knock-in; variant of uncertain significance.

PubMed Disclaimer

References

REFERENCES

    1. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18(7):696-704.
    1. Wortmann SB, Oud MM, Alders M, et al. How to proceed after "negative" exome: a review on genetic diagnostics, limitations, challenges, and emerging new multiomics techniques. J Inherit Metab Dis. 2022;45(4):663-681.
    1. Yépez VA, Gusic M, Kopajtich R, et al. Clinical implementation of RNA sequencing for Mendelian disease diagnostics. Genome Med. 2022;14(1):38.
    1. Kopajtich R, Smirnov D, Stenton SL, et al. Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders. medRxiv. 2021. doi:10.1101/2021.03.09.21253187
    1. Kremer LS, Bader DM, Mertes C, et al. Genetic diagnosis of mendelian disorders via RNA sequencing. Nat Commun. 2017;8:15824.

Publication types